Dark

Check out our Level2View

ADGI
Adagio Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Sep 13, 2022

4.83USD+4.095%(+0.19)549,975

Pre-market

0.00USD-100.000%(-4.64)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 13, 2022

02:24PM EST Adagio Therapeutics shares were trading higher after the company summarized recent findings reported in three separate publications that show ADG20 has neutralization activity against Omicron. Benzinga

11:47AM EST Adagio Therapeutics Shares Down 3%; Hearing Morgan Stanley Reiterates Underweight Rating, $6 Price Target Benzinga

11:47AM EST The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact Benzinga

Jan 12, 2022

05:00PM EST UPDATE: Adagio Says 'Multiple Efforts Underway to Address Omicron and Potential Future SARS-CoV-2 Variants' Benzinga

04:59PM EST Adagio Therapeutics Highlights 'Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron' Benzinga

04:57PM EST Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron GlobeNewswire Inc

Jan 11, 2022

05:56AM EST Adagio Therapeutics Granted U.S. Patent #11,220,536 'Compounds specific to coronavirus S protein and uses thereof' Benzinga

Jan 6, 2022

10:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022 Benzinga

08:14AM EST Morgan Stanley Downgrades Adagio Therapeutics to Underweight, Lowers Price Target to $6 Benzinga

06:30AM EST Adagio Therapeutics to Present at the 40th Annual J.P. Morgan GlobeNewswire Inc

Dec 22, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021 Benzinga

07:51AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

05:37AM EST Jefferies Downgrades Adagio Therapeutics to Hold, Lowers Price Target to $10 Benzinga

Dec 17, 2021

08:00AM EST Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in PR Newswire

Dec 16, 2021

03:40PM EST Watching Adagio Therapeutics Shares Following US Patent & Trademark Office Abstract For Co.'s 'COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF' Benzinga

02:31PM EST Mid-Afternoon Market Update: Nasdaq Down 2.5%; Calliditas Therapeutics Shares Spike Higher Benzinga

12:23PM EST Mid-Day Market Update: Gold Rises 2%; IronNet Shares Plummet Benzinga

10:24AM EST Mid-Morning Market Update: Markets Mixed; Accenture Beats Q1 Estimates Benzinga

10:14AM EST Adagio Therapeutics Shares Spike To Session High; Traders Circulate Reiterated Buy Rating, $46 Price Target From Jefferies Benzinga

Dec 15, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 Benzinga

08:48AM EST Morgan Stanley Downgrades Adagio Therapeutics to Equal-Weight, Lowers Price Target to $11 Benzinga

07:26AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

07:01AM EST Guggenheim Downgrades Adagio Therapeutics to Neutral Benzinga

05:17AM EST Stifel Downgrades Adagio Therapeutics to Hold, Lowers Price Target to $9 Benzinga

Dec 14, 2021

02:39PM EST Mid-Afternoon Market Update: Dow Falls 100 Points; Terminix Shares Spike Higher Benzinga

12:40PM EST Mid-Day Market Update: Nasdaq Tumbles 200 Points; MIND Technology Shares Jump Benzinga

10:13AM EST Mid-Morning Market Update: Markets Mostly Lower; Producer Prices Rise 0.8% In November Benzinga

10:12AM EST Mid-Morning Market Update: Markets; Producer Prices Rise 0.8% In November Benzinga

08:24AM EST UPDATE: Adagio Says Is Evaluating Next Steps For ITs ADG20 Program Benzinga

08:24AM EST UPDATE: Adagio Said It Plans To Pause Patient Recruitment In Its Phase 2/3 COVID-19 Treatment Trial, Cites Emergence Of Omicron As Dominant Variant In South Africa Benzinga

08:24AM EST UPDATE: Adagio Says Based On In Vitro Findings Related To Omicron, Co. Plans To Pause Patient Recruitment In Phase 2/3 COVID-19 Treatment Trial At Clinical Sites In South Africa Benzinga

07:13AM EST Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant Benzinga

07:00AM EST Adagio Therapeutics Reports Reduction in In Vitro Neutralizing GlobeNewswire Inc

Dec 7, 2021

06:53AM EST Adagio Therapeutics Granted U.S. Patent #11,192,940 'Compounds specific to coronavirus S protein and uses thereof' Benzinga

Dec 1, 2021

03:39PM EST Adagio Therapeutics shares were trading lower as the stock pulls back following a surge in recent sessions. Benzinga

Nov 30, 2021

04:56PM EST EXCLUSIVE: Adagio Therapeutics Inc Co-Founder and CEO, Tillman Gerngross Now Interviewing On Benzinga's Live Tv Benzinga

04:54PM EST EXCLUSIVE: Adagio Therapeutics Inc Co-Founder and CEO, Tillman Gerngross To Appear On Benzinga's Live Tv At 12:15 p.m. ET Benzinga

04:52PM EST Mid-Morning Market Update: Markets Mostly Lower; JinkoSolar Issues Weak Sales Forecast Benzinga

04:49PM EST Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Nov. 30, 2021: TWTR, BNTX, COST, MRVL, ADGI Benzinga

04:21PM EST Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher Benzinga

04:17PM EST Watching Adagio Therapeutics Shares; Co's CEO To Appear On CNBC Shortly Benzinga

04:11PM EST Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide Benzinga

04:04PM EST Mid-Morning Market Update: Markets Open Higher; Li Auto Sales Top Views Benzinga

04:03PM EST Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 Benzinga

Nov 29, 2021

07:13AM EST Morgan Stanley Upgrades Adagio Therapeutics to Overweight, Announces $49 Price Target Benzinga

06:35AM EST Adagio Therapeutics Reports That None Of The Mutations Present In SARS-CoV-2 Variant, Omicron, Are Associated With Escape From ADG20 Neutralization In Vitro Benzinga

06:30AM EST Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing GlobeNewswire Inc

Nov 26, 2021

11:47AM EST Mid-Day Market Update: Dow Tumbles Over 900 Points; Crude Oil Down 12% Benzinga

10:13AM EST Mid-Morning Market Update: Markets Open Lower; Europe's Regulator Backs Pfizer's COVID-19 Vaccine For Kids Aged 5-11 Years Benzinga

Nov 22, 2021

06:30AM EST Adagio Therapeutics Announces Expansion of Management Team and GlobeNewswire Inc

Nov 15, 2021

10:50AM EST Adagio Therapeutics Says, 'We recently received clear feedback from the FDA on a strategy to submit an EUA for ADG20 for the prevention of COVID-19, and have initiated efforts to expand our clinical program to additional patient subsets...' Benzinga

10:49AM EST Adagio Therapeutics Q3 EPS $(0.98) Benzinga

06:30AM EST FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID-19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second Quarter 2022 GlobeNewswire Inc

Nov 10, 2021

06:30AM EST Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced participation in the following upcoming investor conferences: GlobeNewswire Inc

Oct 19, 2021

06:33AM EDT Adagio Therapeutics Announced New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants Benzinga

06:30AM EDT Adagio Therapeutics Announces New In Vitro Data Highlighting Broad GlobeNewswire Inc

Oct 1, 2021

12:47PM EDT Mid-Day Market Update: Dow Surges 300 Points; Omeros Shares Plummet Benzinga

10:21AM EDT Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Rises In September Benzinga

Sep 29, 2021

07:58AM EDT Adagio Therapeutics Inc. (ADGI) announced new data highlighting the potential of ADG20 for the treatment and prevention of covid-19. RTTNews

07:22AM EDT Adagio Reports New Data From COVID-19 Program; Says ADG20 Continues To Be Well Tolerated In Healthy Volunteers RTTNews

06:31AM EDT Adagio Therapeutics Announces New Data Highlighting 'the Potential of ADG20 for Treatment and Prevention of COVID-19' Benzinga

06:30AM EDT ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study GlobeNewswire Inc

06:30AM EDT Adagio Therapeutics to Participate in the Guggenheim 2nd Annual GlobeNewswire Inc

Sep 20, 2021

06:34AM EDT Adagio Therapeutics Q2 EPS $(0.18) Benzinga

Sep 14, 2021

02:49PM EDT Mid-Afternoon Market Update: Dow Tumbles 300 Points; Communications Systems Shares Climb Benzinga

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

Sep 10, 2021

07:36PM EDT Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial Benzinga

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

07:10AM EDT Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced Friday the expansion of patient population in global EVADE phase 2/3 clinical trial of ADG20 for the prevention of COVID-19. RTTNews

06:35AM EDT Adagio Therapeutics Expands Patient Population In Global Phase 2/3 Trial Of ADG20 For COVID-19 RTTNews

06:33AM EDT Adagio Therapeutics Announces Expansion Of Patient Population In Global Phase 2/3 Clinical Trial Of ADG20 For The Prevention of COVID-19 Benzinga

Sep 3, 2021

07:31AM EDT The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself Benzinga

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Sep 1, 2021

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

Aug 31, 2021

11:44AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2021 Benzinga

06:04AM EDT Morgan Stanley Initiates Coverage On Adagio Therapeutics with Equal-Weight Rating, Announces Price Target of $33 Benzinga

06:03AM EDT Jefferies Initiates Coverage On Adagio Therapeutics with Buy Rating, Announces Price Target of $60 Benzinga

06:02AM EDT Stifel Initiates Coverage On Adagio Therapeutics with Buy Rating, Announces Price Target of $57 Benzinga

06:01AM EDT Guggenheim Initiates Coverage On Adagio Therapeutics with Buy Rating, Announces Price Target of $40 Benzinga

Aug 29, 2021

09:48AM EDT The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 6, 2021

11:29AM EDT Adagio Therapeutics Shares Open For Trade At $21; IPO Priced At $17/Share Benzinga

09:33AM EDT Adagio Therapeutics Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $17/Share Benzinga

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Share